Back to Search Start Over

A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing.

Authors :
Stevens CS
Carmichael JC
Watkinson R
Kowdle S
Reis RA
Hamane K
Jang J
Park A
Pernet O
Khamaikawin W
Hong P
Thibault P
Gowlikar A
An DS
Lee B
Source :
Journal of virology [J Virol] 2024 Nov 04, pp. e0083224. Date of Electronic Publication: 2024 Nov 04.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

The therapeutic potential of gene editing technologies hinges on the development of safe and effective delivery methods. In this study, we developed a temperature-sensitive and less immunogenic Sendai virus (ts SeV) as a novel delivery vector for CRISPR-Cas9 and for efficient gene editing in sensitive human cell types with limited induction of an innate immune response. ts SeV demonstrates high transduction efficiency in human CD34 <superscript>+</superscript> hematopoietic stem and progenitor cells (HSPCs) including transduction of the CD34 <superscript>+</superscript> /CD38 <superscript>-</superscript> /CD45RA <superscript>-</superscript> /CD90 <superscript>+</superscript> (Thy1 <superscript>+</superscript> )/CD49f <superscript>high</superscript> stem cell enriched subpopulation. The frequency of CCR5 editing exceeded 90% and bi-allelic CCR5 editing exceeded 70% resulting in significant inhibition of HIV-1 infection in primary human CD14 <superscript>+</superscript> monocytes. These results demonstrate the potential of the ts SeV platform as a safe, efficient, and flexible addition to the current gene-editing tool delivery methods, which may help further expand the possibilities in personalized medicine and the treatment of genetic disorders.<br />Importance: Gene editing has the potential to be a powerful tool for the treatment of human diseases including HIV, β-thalassemias, and sickle cell disease. Recent advances have begun to overcome one of the major limiting factors of this technology, namely delivery of the CRISPR-Cas9 gene editing machinery, by utilizing viral vectors. However, gene editing therapies have yet to be implemented due to inherent risks associated with the DNA viral vectors typically used for delivery. As an alternative strategy, we have developed an RNA-based Sendai virus CRISPR-Cas9 delivery vector that does not integrate into the genome, is temperature sensitive, and does not induce a significant host interferon response. This recombinant SeV successfully delivered CRISPR-Cas9 in primary human CD14+ monocytes ex vivo resulting in a high level of CCR5 editing and inhibition of HIV infection.

Details

Language :
English
ISSN :
1098-5514
Database :
MEDLINE
Journal :
Journal of virology
Publication Type :
Academic Journal
Accession number :
39494910
Full Text :
https://doi.org/10.1128/jvi.00832-24